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potential biomarkers. Argon was used as a collision gas, and the collision energy was adjusted from 10 eV to 40 eV for each analyte.
All raw chromatograms were processed with Profile Analysis 2.0 (Bruker, USA). The main parameters were: retention time range = 1.5-9.5 min, mass window = 0.5 Dalton, and retention time window = 1 min. To reduce variations from sample injection and enrichment factors, the intensity of extracted metabolites was normalized to the total areas for all urine samples. After peak deconvolution, alignment, integration and normalization, a table containing retention time, exact mass pairs and normalized peak areas were extracted from raw chromatograms.
All data in this table were Pareto-scaled and then introduced to SIMCA-P v11.5 software (Umetrics, Sweden) for multivariate statistical analysis. A tight QC clustering was observed in the scores plot following principal component analysis (ESI, Figure S1 ), indicating the quality of the data was good for further analysis. In order to investigate the arsenic induced metabolome alteration, the dataset was divided into quintiles based upon arsenic levels. The 1st quintile was defined as lowest-level exposure group, while the 5th quintile was defined as highest-level exposure group. Partial least squares discriminant analysis (PLS-DA), a supervised pattern recognition approach, was used for group differentiation (lowest-level exposure group vs.
highest-level exposure group) of urine samples. The 999-time permutation test was performed to validate the developed PLS-DA models (ESI, Figure S2 ). Biomarkers were screened from the most robust PLS-DA model, and iAs-based PLS-DA model. Extracted variables that contributed the most in the group distinction were considered potential biomarkers. Here, we adopted strict criteria to select the biomarker: (1) VIP scores of the variables > 3 (ESI, Figure S3) ; (2) jack-knifing confidence interval of the variables >0 (Supplement Figure S1) ; (3) p value of the variables between 1 st and 5 th quintiles< 0.01; and (4) the variables significantly correlated with urinary iAs after adjusted by age, BMI, smoking and drinking status.
Biomarker Identification
The detailed method for biomarker identification was described previously (Zhang et al. J Pharm Biomed Anal. 2012, 66:287-97; Peng et al. J Pharm Biomed Anal. 2013, 86:56-64 
Quality Control
A quality control (QC) sample was prepared by mixing aliquots of each sample together. For arsenic determination and metabolic profile acquisition, one QC and one blank sample were periodically injected to monitor the stability and reproducibility of analytical measurements using both HPLC/ICP-MS and HPLC/ESI-MS and to monitor any sample carryover during batch analysis. In this study, the arsenic species analysis was validated by reference standards of Figure S1 ). These QC data suggested the data were robust and the quality of the data was good for further analysis (Want et al.
Nat. Protoc. 2010 Protoc. , 5:1005 Protoc. -1018 . No sample carryover was observed during the study. b Smoking history was defined as either 1 = never smoked and past smoker or 2 = current smoker c drinking history was defined as either 1 = never drunk and past drinker or 2 = current drinker d current numbers of principal components (PCs).
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e not available.
*R2Y and Q2 (cum) are usually used to evaluate the quality of PLS-DA model. R2Y is the fraction of the sum of square of the entire Y's, which is explained by the current principal components (PCs) and represents the variance of Y variable. Q2 (cum) reflects the cumulative cross-validated percent of the total variation of the X's and Y's, which can be predicted by the current PCs in the PLS-DA model.
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Table S4
Areas under receiver operator characteristic curve (AUC) and the statistic significances of iAs and total arsenic-based models. 
Biomarker
